Healthcare provider profile · identity verified

Ranjana S Nathan, MD

Internal Medicine · TIGARD, OR · NPI 1588690127

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	852	256
Levothyroxine Sodium	Levothyroxine Sodium	604	170
Amlodipine Besylate	Amlodipine Besylate	506	136
Losartan Potassium	Losartan Potassium	391	113
Metoprolol Succinate	Metoprolol Succinate	380	102
Omeprazole	Omeprazole	288	84
Gabapentin	Gabapentin	269	88
Lisinopril	Lisinopril	255	74
Alendronate Sodium	Alendronate Sodium	226	63
Eliquis	Apixaban	210	36
Clonidine Hcl	Clonidine Hcl	205	57
Metformin Hcl Er	Metformin Hcl	197	60
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	184	57
Citalopram Hbr	Citalopram Hydrobromide	169	54
Montelukast Sodium	Montelukast Sodium	169	50
Potassium Chloride	Potassium Chloride	163	45
Rosuvastatin Calcium	Rosuvastatin Calcium	151	44
Trazodone Hcl	Trazodone Hcl	145	42
Escitalopram Oxalate	Escitalopram Oxalate	134	36
Bupropion Xl	Bupropion Hcl	129	40
Metformin Hcl	Metformin Hcl	122	42
Prednisone	Prednisone	120	76
Spironolactone	Spironolactone	118	35
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	114	37
Duloxetine Hcl	Duloxetine Hcl	112	31
Sertraline Hcl	Sertraline Hcl	104	28
Albuterol Sulfate Hfa	Albuterol Sulfate	102	47
Donepezil Hcl	Donepezil Hcl	101	16
Furosemide	Furosemide	99	32
Hydrochlorothiazide	Hydrochlorothiazide	96	29
Pravastatin Sodium	Pravastatin Sodium	82	19
Oxybutynin Chloride Er	Oxybutynin Chloride	79	32
Estradiol	Estradiol	77	31
Fluoxetine Hcl	Fluoxetine Hcl	76	19
Atenolol	Atenolol	75	20
Allopurinol	Allopurinol	74	19
Metoprolol Tartrate	Metoprolol Tartrate	74	21
Tamsulosin Hcl	Tamsulosin Hcl	74	20
Bupropion Hcl Sr	Bupropion Hcl	73	17
Pantoprazole Sodium	Pantoprazole Sodium	69	23
Simvastatin	Simvastatin	67	18
Finasteride	Finasteride	65	16
Glipizide Er	Glipizide	65	21
Mirtazapine	Mirtazapine	61	16
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	60	16
Famotidine	Famotidine	57	21
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	56	19
Triamcinolone Acetonide	Triamcinolone Acetonide	56	31
Carvedilol	Carvedilol	55	14
Dicyclomine Hcl	Dicyclomine Hcl	53	17
Memantine Hcl	Memantine Hcl	52	suppressed
Nifedipine Er	Nifedipine	52	15
Alprazolam	Alprazolam	46	16
Synthroid	Levothyroxine Sodium	44	13
Hydroxyzine Hcl	Hydroxyzine Hcl	43	21
Warfarin Sodium	Warfarin Sodium	43	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	43	12
Quetiapine Fumarate	Quetiapine Fumarate	41	suppressed
Buspirone Hcl	Buspirone Hcl	40	19
Propranolol Hcl	Propranolol Hcl	40	13
Meloxicam	Meloxicam	36	17
Baclofen	Baclofen	35	16
Prazosin Hcl	Prazosin Hcl	34	suppressed
Tizanidine Hcl	Tizanidine Hcl	34	16
Fluconazole	Fluconazole	33	21
Torsemide	Torsemide	32	11
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	32	suppressed
Xarelto	Rivaroxaban	32	suppressed
Azelastine Hcl	Azelastine Hcl	30	11
Glipizide	Glipizide	30	suppressed
Ibandronate Sodium	Ibandronate Sodium	30	suppressed
Tramadol Hcl	Tramadol Hcl	30	11
Methimazole	Methimazole	28	suppressed
Jardiance	Empagliflozin	27	suppressed
Lorazepam	Lorazepam	27	17
Ozempic	Semaglutide	27	suppressed
Ropinirole Hcl	Ropinirole Hcl	27	suppressed
Lovastatin	Lovastatin	26	suppressed
Ezetimibe	Ezetimibe	25	suppressed
Fluticasone Propionate	Fluticasone Propionate	25	11
Galantamine Er	Galantamine Hbr	25	suppressed
Celecoxib	Celecoxib	23	13
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	23	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	22	suppressed
Hydralazine Hcl	Hydralazine Hcl	22	suppressed
Propranolol Hcl Er	Propranolol Hcl	22	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	22	suppressed
Lamotrigine	Lamotrigine	21	suppressed
Verapamil Er	Verapamil Hcl	21	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	19	17
Cephalexin	Cephalexin	18	16
Fenofibrate	Fenofibrate	18	suppressed
Chlorthalidone	Chlorthalidone	17	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	17	suppressed
Methocarbamol	Methocarbamol	17	suppressed
Valsartan	Valsartan	17	suppressed
Amiodarone Hcl	Amiodarone Hcl	15	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	15	suppressed
Clopidogrel	Clopidogrel Bisulfate	15	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	15	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	15	suppressed
Ondansetron Odt	Ondansetron	15	suppressed
Paroxetine Hcl	Paroxetine Hcl	15	suppressed
Topiramate	Topiramate	15	suppressed
Azithromycin	Azithromycin	14	12
Farxiga	Dapagliflozin Propanediol	14	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	14	12
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	13	suppressed
Humalog Kwikpen U-100	Insulin Lispro	13	suppressed
Amoxicillin	Amoxicillin	12	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	12	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	12	suppressed
Terazosin Hcl	Terazosin Hcl	12	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	12	suppressed
Dilt-Xr	Diltiazem Hcl	11	suppressed
Fenofibrate	Fenofibrate,micronized	11	suppressed
Oxycodone Hcl	Oxycodone Hcl	11	suppressed
Pregabalin	Pregabalin	11	suppressed
Sucralfate	Sucralfate	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error